Chapter 24: Schizophrenia Spectrum & Psychotic Disorders

Schizophrenia Spectrum & Psychotic Disorders begins by tracing the diagnostic history from Kraepelin’s biological perspective on dementia praecox to Bleuler’s more optimistic introduction of the term schizophrenia and his identified "four A’s": affective disturbance, autism, associative looseness, and ambivalence. Modern diagnosis is guided by DSM-5 criteria, which requires a significant decline in functioning and the presence of symptoms such as delusions, hallucinations, or disorganized speech. A critical clinical distinction is made between Type I positive symptoms, which represent an exaggeration of normal functions (like hallucinations) often linked to dopamine excess in the limbic system, and Type II negative symptoms, which involve a loss of function (such as apathy or social withdrawal) associated with structural brain changes and reduced dopamine in cortical areas. The etiology of these disorders is explored through the vulnerability-stress model, which suggests that biological predispositions—including genetic heritability reaching up to 90 percent and neurostructural anomalies like enlarged ventricles—interact with environmental stressors to trigger the illness. Management is presented via a tripartite psychotherapeutic approach: building a trust-based nurse-patient relationship focused on reality testing, navigating the complexities of typical and atypical antipsychotic pharmacology to manage side effects like metabolic syndrome and extrapyramidal symptoms, and manipulating the therapeutic milieu to maintain a safe, low-stimulus environment. Additionally, the text addresses common comorbidities such as substance abuse and depression, while differentiating schizophrenia from related conditions like schizoaffective, delusional, and brief psychotic disorders.